Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.47 |
| ▸ | JAK1 | P23458 | 7/20 | 0.42 |
| ▸ | JAK2 | O60674 | 5/20 | 0.42 |
| ▸ | JAK3 | P52333 | 5/20 | 0.42 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 4/20 | 0.40 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2795109 | 0.89 | KCNH2 (0.49) | KCNH2KCNQ1CACNA1CMCHR1 | |
| SCHEMBL2799086 | 0.89 | KCNH2 (0.53) | KCNH2JAK1JAK2JAK3KCNQ1 | |
| Hydrochloric Acid SCHEMBL2796540 | 0.89 | KCNH2 (0.48) | KCNH2KCNQ1CACNA1CMCHR1 | |
| SCHEMBL2797811 | 0.87 | KCNH2 (0.53) | KCNH2JAK1JAK2JAK3KCNQ1 | |
| SCHEMBL2798563 | 0.87 | KCNH2 (0.52) | KCNH2KCNQ1CACNA1CMCHR1 | |
| SCHEMBL2799498 | 0.87 | KCNH2 (0.51) | KCNH2JAK1JAK2JAK3KCNQ1 | |
| SCHEMBL2799493 | 0.87 | KCNH2 (0.51) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL2796722 | 0.86 | KCNH2 (0.49) | KCNH2KCNQ1CACNA1C | |
| Hydrochloric Acid SCHEMBL2794073 | 0.86 | KCNH2 (0.50) | KCNH2KCNQ1CACNA1C | |
| SCHEMBL2798961 | 0.86 | KCNH2 (0.52) | KCNH2KCNQ1CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8329694-B2 | Quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2468743-A1 | Nitrogen-containing bicyclic compounds useful as antibacterial agents | Toyama Chemical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168418-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | ROS1, NOX1, ARG1 | KCNH2 578/4885JAK1 54/4885JAK2 20/4885 |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | KCNH2 525/4885JAK1 943/4885JAK2 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.